The Kratom Herald

Mitragyna Speciosa News And Information

Pro-Kratom Congressional Representatives Request Meeting With FDA Commissioner

kratom fda

There is a ticker on the bottom of the American Kratom Association (AKA) website which says that the Food and Drug Administration (FDA) has ignored a meeting request from the AKA for 663 days now. Essentially, the FDA is completely ignoring the AKA and refuses to talk to pro-Kratom advocates, and this is a major problem because the FDA has continued to persistently release misinformation about Kratom.

Now a group of Congressional Representatives is trying to change this, and is pushing to get a meeting with FDA Commissioner Steven M. Hahn. Specifically, Utah Senator Curtis S. Bramble, Tony Rivero from the Arizona House of Representatives, Jim Wheeler from the Nevada Assembly, and Vernon Jones from the Georgia House of Representatives have sent a letter to the FDA Commissioner which can be read at this link: Letter to FDA Commissioner Hahn

Notably, all 4 of these congressional representatives are from states which have passed the Kratom Consumer Protection Act (KCPA).

In the letter the Congressional Representatives note that Kratom has been used in the United States since the early 1970s, and has been safely used in Southeast Asia for centuries, and that 10-15 million Americans currently use Kratom to enhance well-being, occupational performance, and social interactions.

The main point of the letter is that FDA Commissioner Hahn said “We know one thing, the American people are using CBD products. People are using these products. We’re not going to be able to say you can’t use these products. It’s a fool’s game to try to even approach that” as well as “We have to be open to the fact that there might be some value in these products and certainly Americans think that is the case. But we want to get them information to help them make the right decisions.”

The Congressional Representatives point out that the same holds true for Kratom, and that the FDA should properly regulate Kratom via the KCPA instead of trying to ban Kratom, since so many Americans use Kratom and depend on it for their well-being.

Also, the Congressional Representatives say that it is obvious that Americans will continue to use Kratom no matter what, and therefore the government needs to act reasonably and responsibly, rather than declaring Kratom illegal which would turn Kratom into a blackmarket and cause multitudes of issues.

Ultimately, the Congressional Representatives who wrote this letter are calling on the FDA to review the science and to look at the Kratom marketplace in a realistic way, in the same way that the FDA is already viewing the CBD marketplace in a reasonable way, rather than continuing to spread misinformation about Kratom.

Finally, the Congressional Representatives are asking the FDA Commissioner to meet with them on a Zoom call, which is extremely convenient, so there’s no excuse for the FDA Commissioner to say no. Now it is just a matter of time to see if the FDA Commissioner will respond in a positive way to this letter.